close

Location

345 Park Ave South,
New York, NY 10010
(212) 547-9879

Investors

Lexeo Therapeutics, taking aim at the cause of genetic diseases

Lexeo

COMPANY Profile

Lexeo Therapeutics is a New York City based clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.

MORE INFORMATION

News Releases

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Read More

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Read More

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Read More
All Press releases

Events

Stifel 2024 Healthcare Conference

Listen to webcast

Interim Phase 1/2 Clinical Data of LX1001 for the Treatment of APOE4-Associated Alzheimer’s Disease – October 2024

Listen to webcast
All Events

Contact Us